Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Business Overview: NAI provides private label contract manufacturing services for nutritional supplements and, following the December 2005 acquisition of Real Health Laboratories (RHL), markets branded nutritional supplements and lifestyle products. The company operates in two segments: NAI (contract manufacturing) and RHL (direct-to-consumer and wholesale branded products).
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2006 | Nine Months Ended Mar 31, 2006 |
|---|---|---|
| Net Sales | $23.3 million | $64.9 million |
| Gross Profit | $6.0 million (25.8% margin) | $14.2 million (22.0% margin) |
| Net Income | $0.6 million | $1.5 million |
| Diluted EPS | $0.09 | $0.22 |
| Cash and Equivalents | $1.6 million | $1.6 million (Ending Balance) |
| Total Debt | $10.9 million | $10.9 million |
| Operating Cash Flow | N/A | ($0.2 million) used |
Material Changes vs. Prior Period
- Revenue: Net sales increased 4% for the quarter ($23.3M vs. $22.5M) but decreased 3% year-to-date ($64.9M vs. $66.8M). The decline in private label contract manufacturing sales (down 9% YTD) was partially offset by the inclusion of RHL sales.
- Profitability: Net income for the quarter surged 124% to $0.6M, driven by a 42% increase in gross profit. However, YTD net income declined 22% to $1.5M due to higher operating expenses and interest costs associated with the acquisition.
- Acquisition Impact: The acquisition of RHL on December 5, 2005, added $2.7M in sales for the quarter and $3.2M YTD. It also resulted in $7.3M of goodwill and significant intangible assets.
- Debt: Total debt increased significantly from $3.8M (June 30, 2005) to $10.9M (March 31, 2006) due to a $3.8M term loan for the RHL acquisition and increased utilization of the working capital line of credit to fund inventory for new customers.
- Cash Flow: Operating cash flow turned negative ($0.2M used) compared to $1.9M provided in the prior year, primarily due to a $9.7M increase in inventory levels.
Guidance, Outlook, and Risks
- Outlook: Management expects to fill orders exceeding $10M from two new private label customers in the fourth quarter of fiscal 2006. The company is integrating RHL operations to achieve cost savings and expand distribution channels.
- Customer Concentration: The company faces high concentration risk. Two customers accounted for 73% of sales in the quarter and 77% YTD. The loss of either would have a material adverse impact.
- Supplier Concentration: Raw material purchases are concentrated, with one supplier accounting for 23% of purchases in the quarter.
- Legal Contingency: A patent infringement lawsuit filed by Novogen Research Pty. Ltd. remains unresolved. The settlement demand has increased to $125,000, though management does not currently expect a material adverse effect.
- Market Risk: The company is exposed to foreign currency fluctuations (Euro and Swiss Franc) and interest rate changes on variable-rate debt. A 10% adverse currency change would reduce YTD net income by approximately $197,000.
Investor Verification Checklist
- Inventory Build: Verify the $9.7M increase in inventory is aligned with confirmed orders from new customers expected to ship in Q4.
- Customer Retention: Monitor sales trends from the top two customers, which represent over 75% of revenue.
- Debt Covenants: Review compliance with amended credit facility covenants, specifically the fixed charge coverage ratio and capital expenditure limits.
- RHL Integration: Assess whether the anticipated cost savings from integrating RHL operations are materializing.
- Legal Resolution: Track the status of the Novogen patent infringement settlement negotiations.